New Haven, CONNECTICUT28 Active Studies

Interstitial Cystitis Clinical Trials in New Haven, CONNECTICUT

Find 28 actively recruiting interstitial cystitis clinical trials in New Haven, CONNECTICUT. Connect with local research sites and explore new treatment options.

28
Active Trials
26
Sponsors
15,620
Enrolling

Recruiting Interstitial Cystitis Studies in New Haven

RecruitingNew Haven, CONNECTICUTNCT02000089

The Cancer of the Pancreas Screening-5 CAPS5)Study

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at thei...

9,000 participants
Johns Hopkins University
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06731478

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus stan...

726 participants
Daiichi Sankyo
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06943872

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia...

630 participants
BeiGene
View Study Details
RecruitingNew Haven, CONNECTICUTNCT05254171

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for me...

600 participants
Panbela Therapeutics, Inc.
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06081894

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM

This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy....

500 participants
Cytokinetics
View Study Details
RecruitingNew Haven, CONNECTICUTNCT05918211

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the F...

436 participants
Mezzion Pharma Co. Ltd
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06395948

A Study Evaluating APG777 in Atopic Dermatitis

This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding...

431 participants
Apogee Therapeutics, Inc.
View Study Details
RecruitingNew Haven, CONNECTICUTNCT05639114

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC)...

406 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNew Haven, CONNECTICUTNCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

316 participants
Simcha IL-18, Inc.
View Study Details
RecruitingNew Haven, CONNECTICUTNCT05948566

Strategy for Improving Stroke Treatment Response

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alp...

300 participants
Translational Sciences, Inc.
View Study Details
RecruitingNew Haven, CONNECTICUTNCT00775476

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack ...

290 participants
State University of New York - Upstate Medical University
View Study Details
RecruitingNew Haven, CONNECTICUTNCT04965675

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine....

285 participants
H. Lundbeck A/S
View Study Details
RecruitingNew Haven, CONNECTICUTNCT05968326

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRIN...

260 participants
Genentech, Inc.
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06389136

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants w...

200 participants
AbbVie
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06481306

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and partic...

184 participants
Bristol-Myers Squibb
View Study Details
RecruitingNew Haven, CONNECTICUTNCT07032662

IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP....

162 participants
Immunovant Sciences GmbH
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06290141

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a max...

160 participants
Sanofi
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06449677

Bionic Pancreas in CFRD

This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using...

150 participants
Jaeb Center for Health Research
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06428019

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutini...

120 participants
AbbVie
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06388564

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in par...

120 participants
Incyte Corporation
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06196203

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed hig...

90 participants
Akeso
View Study Details
RecruitingNew Haven, CONNECTICUTNCT05475925

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular ...

69 participants
Dren Bio
View Study Details
RecruitingNew Haven, CONNECTICUTNCT05092347

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in nee...

56 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingNew Haven, CONNECTICUTNCT04792502

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modifi...

52 participants
Brown University
View Study Details
RecruitingNew Haven, CONNECTICUTNCT03128996

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benef...

29 participants
Washington University School of Medicine
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06322342

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain t...

24 participants
Reveal Pharmaceuticals Inc.
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06328777

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis...

12 participants
Cabaletta Bio
View Study Details
RecruitingNew Haven, CONNECTICUTNCT06121297

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus...

12 participants
Cabaletta Bio
View Study Details

About Interstitial Cystitis Clinical Trials in New Haven

Interstitial cystitis/bladder pain syndrome is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. It primarily affects women and can significantly impact quality of life. Treatment includes dietary changes, bladder instillations, oral medications, and neuromodulation.

There are currently 28 interstitial cystitis clinical trials recruiting participants in New Haven, CONNECTICUT. These studies are seeking a combined 15,620 participants. Research is being sponsored by Johns Hopkins University, Daiichi Sankyo, BeiGene and 23 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Interstitial Cystitis Clinical Trials in New Haven — FAQ

Are there interstitial cystitis clinical trials in New Haven?

Yes, there are 28 interstitial cystitis clinical trials currently recruiting in New Haven, CONNECTICUT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What interstitial cystitis treatments are being tested?

The 28 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for interstitial cystitis.

Data updated March 2, 2026 from ClinicalTrials.gov